Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis

Internal Medicine

Volumn 51, Issue 13, 2012, Pages 1683-1688

  Hashimoto, Atsushi ^a,b   Arinuma, Yoshiyuki ^b   Nagai, Tatsuo ^a   Tanaka, Sumiaki ^a   Matsui, Toshihiro ^b   Tohma, Shigeto ^b   Endo, Hirahito ^c   Hirohata, Shunsei ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Interstitial lung diseases; Japan; Lung cancer; Malignancy; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; SCL 70 ANTIBODY;

ADENOCARCINOMA; ADULT; ARTICLE; AUTOPSY; BREAST CANCER; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; INTERSTITIAL LUNG DISEASE; JAPANESE; LUNG CANCER; LUNG LESION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; STANDARDIZED INCIDENCE RATIO; STOMACH CANCER; SYSTEMIC SCLEROSIS;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHILD; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84863505062     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7686     Document Type: Article

References (46)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66: 940-944, 2007.
2. Hashimoto A, Tejima S, Tono T, et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 38: 1931-1939, 2011.
3. Barnett AJ, Coventry DA. Scleroderma. 1. Clinical features, course of illness and response to treatment in 61 cases. Med J Aust 1: 992-1001, 1969.
4. Hashimoto A, Endo H, Kondo H, Hirohata S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2011 [Epub ahead of print].
5. Doria A, Ghirardello A, de Zambiasi P, Ruffatti A, Gambari PF. Japanese diagnostic criteria for mixed connective tissue disease in Caucasian patients. J Rheumatol 19: 259-264, 1992.
6. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 15: 276-283, 1988.
7. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202-205, 1988.
8. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 27: 563-594, 1998.
9. Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76: 779-786, 1984.
10. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005.
11. Hatano S, Strasser T. Primary Pulmonary Hypertension: Report on a WHO Meeting, Geneva 15-17 October 1973. World Health Organization, Geneva, 1975.
12. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124: 2098-2104, 2003.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.
15. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren syndrome (1999): availability and validity. Mod Rheumatol 14: 425-434, 2004.
16. Cancer incidence in Japan, 1985-89: re-estimation based on data from eight population-based cancer registries. The Research Group for Population-based Cancer Registration in Japan. Jpn J Clin Oncol 28: 54-67, 1998.
17. Ajiki W, Tsukuma H, Oshima A; Research Group for Populationbased Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 34: 352-356, 2004.
18. Katzka DA, Reynolds JC, Saul SH, et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med 82: 46-52, 1987.
19. Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol 115: 950-955, 1979.
20. Black KA, Zilko PJ, Dawkins RL, Armstrong BK, Mastaglia GL. Cancer in connective tissue disease. Arthritis Rheum 25: 1130-1133, 1982.
21. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 52: 2415-2424, 2005.
22. Roumm AD, Medsger TA Jr. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 28: 1336-1340, 1985.
23. Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 52: 531-533, 1993.
24. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 36: 460-464, 1993.
25. Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 76: 910-914, 1995.
26. Higuchi M, Horiuchi T, Ishibashi N, Yoshizawa S, Niho Y, Nagasawa K. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 19: 123-126, 2000.
27. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62: 728-731, 2003.
28. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 33: 1113-1116, 2006.
29. Kang KY, Yim HW, Kim IJ, et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol 38: 299-303, 2009.
30. Olesen AB, Svaerke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 163: 800-806, 2010.
31. Fuse Y, Masuyama J, Yoshio T, et al. Progressive systemic sclerosis (PSS) and cancer: increasing coincidence rate of cancer in 67 PSS patients. Ryumachi 35: 25-31, 1995 (in Japanese, abstract in English).
32. Nishioka K, Katayama I, Kondo H, et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 23: 677-682, 1996.
33. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM. Incidence of lung cancer in systemic sclerosis. J Rheumatol 12: 1136-1139, 1985.
34. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 1: 106-111, 2001.
35. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35: 496-499, 1980.
36. Matsushita H, Tanaka S, Saiki Y, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int 45: 925-932, 1995.
37. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161: 5-8, 2000.
38. Samet JM. Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med 161: 1-2, 2000.
39. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91 (Suppl 2): S3-S10, 2004.
40. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 11: 431-437, 2005.
41. Morita T. A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res 93: 15-23, 2002.
42. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165: 2337-2344, 2005.
43. Rothfield N, Kurtzman S, Vazques-Abad D, Charron C, Daniels L, Greenberg B. Association of anti-topoisomerase I with cancer. Arthritis Rheum 35: 724, 1992.
44. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 66: 551-553, 2007.
45. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62: 2787-2795, 2010.
46. Airo' P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38: 1329-1334, 2011.